The Obstructive Sleep Apnea drugs in development market research report provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Obstructive Sleep Apnea. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for Obstructive Sleep Apnea by 17 companies/universities/institutes. The top development phase for Obstructive Sleep Apnea is phase ii with 15 drugs in that stage. The Obstructive Sleep Apnea pipeline has 23 drugs in development by companies and five by universities/ institutes. Some of the companies in the Obstructive Sleep Apnea pipeline products market are: Shionogi-Apnimed Sleep Science, Brigham and Women’s Hospital and Apnimed.
The key targets in the Obstructive Sleep Apnea pipeline products market include Sodium Dependent Noradrenaline Transporter, Orexin Receptor Type 2, and Orexin/Hypocretin Receptor Type 1.
The key mechanisms of action in the Obstructive Sleep Apnea pipeline product include Sodium Dependent Noradrenaline Transporter Inhibitor with five drugs in Phase III. The Obstructive Sleep Apnea pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Obstructive Sleep Apnea pipeline products market including Small Molecule, and Synthetic Peptide.
Obstructive Sleep Apnea overview
Obstructive sleep apnea (OSA) is defined by episodes of either complete collapse or partial collapse of the airway during sleep, accompanied by a reduction in oxygen saturation or awakening from sleep. This disruption leads to fragmented and nonrestorative sleep. The implications of OSA extend to various aspects of health, including cardiovascular well-being, mental health, overall quality of life, and safety while driving fatigue and reduced productivity. Moreover, OSA poses risks to driving safety, as drowsiness from poor sleep can lead to accidents, emphasizing the need for early diagnosis and effective management.
For a complete picture of Obstructive Sleep Apnea’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
